FLT3/ITD Associated with an Immature Immunophenotype in PML-RARα Leukemia

Overview

Journal Hematol Rep

Publisher MDPI

Date 2013 Jan 29

PMID 23355940

Citations 3

Authors

Mariko Takenokuchi

Seiji Kawano

Yuji Nakamachi

Yasuyuki Sakota

Meilani Syampurnawati

Katsuyasu Saigo

Eiji Tatsumi

Shunichi Kumagai

Affiliations

Soon will be listed here.

Abstract

Acute promyelocytic leukemia (APL) is characterized by the specific PML-RARα fusion gene resulting from translocation t(15;17) (q22;q12). Internal tandem duplication (ITD) of the FLT3 gene has been observed in approximately 35% of APLs, and large-scale studies have identified the presence of ITD as an adverse prognostic factor for acute myeloblastic leukemia (AML) patients. Aberrant expressions of surface antigens, such as CD2, CD34, and CD56, have been found in APL, but the implications of this are not well understood. We investigated the incidence of the FLT3/ITD mutation and FLT3/D835 (I836) point mutation in 25 APL patients. Incidence ratios of FLT3/ITD, D835 (I836), and both FLT3/ITD and D835 (I836) were 36%, 36% and 8%, respectively. FLT3/ITD(+) cases showed a predominance of the bcr3 isoform (P=0.008) and M3v morphology (P<0.001). We found that all FLT3/ITD(+) cases expressed CD2 (9 of 9) more frequently than that of FLT3/ITD(-) (1 of 16) (P<0.001), while only one of the CD2(+) cases (1 of 10, 10%) did not harbor FLT3/ITD, and all CD2(+)CD34(+) cases (5 of 5, 100%) harbored FLT3/ITD. In addition, quantitative polymerase chain reaction analysis showed that FLT3 mRNA was more abundantly expressed in FLT3/ITD(+) than that in FLT3/ITD(-) (P=0.025), while there was no difference between D835(I836) (+) and D835(I836)(-) with regards to aberrant surface-antigen expression, expression levels of FLT3 mRNA, M3v morphology, and the bcr3 isoform of PML-RARα mRNA. This study demonstrates that the presence of FLT3/ITD, but not D835 (I836), is closely related to aberrant CD2 expression and high expression levels of FLT3 mRNA. Our findings also suggest that FLT3/ITD as a secondary genetic event may block differentiation at the immature stage of APL.

Citing Articles

Association between Immunophenotypic Parameters and Molecular Alterations in Acute Myeloid Leukemia.

DE Pinho Pessoa F, Machado C, Barreto I, Sampaio G, DE Sousa Oliveira D, Ribeiro R Biomedicines. 2023; 11(4).

PMID: 37189716 PMC: 10135936. DOI: 10.3390/biomedicines11041098.

Targeted Informatics for Optimal Detection, Characterization, and Quantification of FLT3 Internal Tandem Duplications Across Multiple Next-Generation Sequencing Platforms.

Tsai H, Brackett D, Szeto D, Frazier R, MacLeay A, Davineni P J Mol Diagn. 2020; 22(9):1162-1178.

PMID: 32603763 PMC: 7479488. DOI: 10.1016/j.jmoldx.2020.06.006.

Flow cytometric analysis of CD64 expression pattern and density in the diagnosis of acute promyelocytic leukemia: a multi-center study in Shanghai, China.

Liu M, Weng X, Gong S, Chen H, Ding J, Guo M Oncotarget. 2017; 8(46):80625-80637.

PMID: 29113330 PMC: 5655225. DOI: 10.18632/oncotarget.20814.

References

Gale R, Hills R, Pizzey A, Kottaridis P, Swirsky D, Gilkes A . Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood. 2005; 106(12):3768-76. DOI: 10.1182/blood-2005-04-1746. View

Shih L, Kuo M, Liang D, Huang C, Lin T, Wu J . Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer. 2003; 98(6):1206-16. DOI: 10.1002/cncr.11636. View

Meshinchi S, Woods W, Stirewalt D, Sweetser D, Buckley J, Tjoa T . Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001; 97(1):89-94. DOI: 10.1182/blood.v97.1.89. View

Rovelli A, Biondi A, Cantu Rajnoldi A, Conter V, Giudici G, Jankovic M . Microgranular variant of acute promyelocytic leukemia in children. J Clin Oncol. 1992; 10(9):1413-8. DOI: 10.1200/JCO.1992.10.9.1413. View

Kottaridis P, Gale R, Frew M, Harrison G, Langabeer S, BELTON A . The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the.... Blood. 2001; 98(6):1752-9. DOI: 10.1182/blood.v98.6.1752. View

Biondi A, Luciano A, Bassan R, Mininni D, Specchia G, Lanzi E . CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint. Leukemia. 1995; 9(9):1461-6. View

Ferrara F, Morabito F, Martino B, Specchia G, Liso V, Nobile F . CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol. 2000; 18(6):1295-300. DOI: 10.1200/JCO.2000.18.6.1295. View

Albano F, Mestice A, Pannunzio A, Lanza F, Martino B, Pastore D . The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34 CD2 hypergranular (M3) and microgranular (M3v) phenotypes. Haematologica. 2006; 91(3):311-6. View

Greaves M, Chan L, Furley A, Watt S, Molgaard H . Lineage promiscuity in hemopoietic differentiation and leukemia. Blood. 1986; 67(1):1-11. View

10.

Rowley J, Golomb H, Dougherty C . 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet. 1977; 1(8010):549-50. DOI: 10.1016/s0140-6736(77)91415-5. View

11.

Paietta E, Andersen J, Gallagher R, Bennett J, Yunis J, Cassileth P . The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study. Leukemia. 1994; 8(7):1108-12. View

12.

Hardianti M, Tatsumi E, Syampurnawati M, Furuta K, Suzuki A, Saigo K . Presence of somatic hypermutation and activation-induced cytidine deaminase in acute lymphoblastic leukemia L2 with t(14;18)(q32;q21). Eur J Haematol. 2004; 74(1):11-9. DOI: 10.1111/j.1600-0609.2004.00338.x. View

13.

Montesinos P, Rayon C, Vellenga E, Brunet S, Gonzalez J, Gonzalez M . Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood. 2010; 117(6):1799-805. DOI: 10.1182/blood-2010-04-277434. View

14.

Lin P, Hao S, Medeiros L, Estey E, Pierce S, Wang X . Expression of CD2 in acute promyelocytic leukemia correlates with short form of PML-RARalpha transcripts and poorer prognosis. Am J Clin Pathol. 2004; 121(3):402-7. DOI: 10.1309/XC8P-9M8N-KQDT-38LB. View

15.

NEAME P, Soamboonsrup P, Leber B, Carter R, Sunisloe L, Patterson W . Morphology of acute promyelocytic leukemia with cytogenetic or molecular evidence for the diagnosis: characterization of additional microgranular variants. Am J Hematol. 1997; 56(3):131-42. DOI: 10.1002/(sici)1096-8652(199711)56:3<131::aid-ajh1>3.0.co;2-z. View

16.

Bennett J, Catovsky D, Daniel M, Flandrin G, GALTON D, Gralnick H . Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985; 103(4):620-5. DOI: 10.7326/0003-4819-103-4-620. View

17.

Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K . Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1997; 11(9):1447-52. DOI: 10.1038/sj.leu.2400756. View

18.

Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S . Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001; 97(8):2434-9. DOI: 10.1182/blood.v97.8.2434. View

19.

Levis M, Small D . FLT3: ITDoes matter in leukemia. Leukemia. 2003; 17(9):1738-52. DOI: 10.1038/sj.leu.2403099. View

20.

Callens C, Chevret S, Cayuela J, Cassinat B, Raffoux E, De Botton S . Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia. 2005; 19(7):1153-60. DOI: 10.1038/sj.leu.2403790. View